Therapeutic Outcome of >10 Cycles of Cabazitaxel for Castration-resistant Prostate Cancer: A Multi-institutional Study.

Abstract

BACKGROUND/AIM:

Cabazitaxel use has usually been limited to up to 10 cycles in most countries according to the protocol in the TROPIC trial. Therefore, clinical data on cabazitaxel use beyond 10 cycles is limited. The aim of this study was to report the therapeutic outcome of cabazitaxel chemotherapy administered for >10 cycles.

PATIENTS AND METHODS:

This study included 74 Japanese patients with prostate cancer between 2014 and 2017. Patients background, and treatment outcomes including PSA decline, progression-free survival, treatment-failure-free survival, overall survival, and adverse events were investigated, comparing patients treated with ≤10 and >10 cycles.

RESULTS:

Patients characteristics were favorable as indicated by the higher number of cycles of prior docetaxel chemotherapy, absence of pain, and absence of bony and visceral metastases among men who received >10 cycles of cabazitaxel. PSA response, progression-free survival, treatment-failure-free survival and overall survival were better among patients treated with >10 cycles of cabazitaxel compared to those treated with ≤10 cycles. The incidence of severe adverse events was similar between the two groups.

CONCLUSION:

Taken together, this study suggested that continuous chemotherapy with cabazitaxel beyond 10 cycles may be beneficial.

• Authors: Masaki Shiota, Motonobu Nakamura, Akira Yokomizo, Toshihisa Tomoda, Naotaka Sakamoto, Narihito Seki, Shuji Hasegawa, Takakazu Yunoki, Masahiko Harano, Kentaro Kuroiwa, Masatoshi Eto
• Journal: Anticancer research (Anticancer Res) Vol. 39 Issue 8 Pg. 4411-4414 (Aug 2019) ISSN: 1791-7530 [Electronic] Greece
• PMID: 31366538 (Publication Type: Clinical Trial, Phase III, Journal Article, Multicenter Study)
• Copyright: Copyright© 2019, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.

Chemical References

• Taxoids
• Docetaxel
• cabazitaxel
• Prostate-Specific Antigen

Topics

• Aged
• Antineoplastic Combined Chemotherapy Protocols (administration & dosage, adverse effects)
• Docetaxel (administration & dosage, adverse effects)
• Drug Administration Schedule
• Humans
• Male
• Middle Aged
• Progression-Free Survival
• Prostate-Specific Antigen (blood)
• Prostatic Neoplasms, Castration-Resistant (blood, drug therapy, pathology)
• Taxoids (administration & dosage, adverse effects)
• Treatment Outcome